Skip to main content


Biocompatibility of new bioactive resin composite versus calcium silicate cements: an animal study

  • 1504 Accesses

  • 1 Citations



The purpose of this study was to compare the biocompatibility of three bioactive materials, namely ACTIVA bioactive restorative resin composite, iRoot BP plus and Mineral Trioxide Aggregate (MTA) Angelus-HP.


Seventy-five Wistar male rats were subjected to subcutaneous implantation of four polyethylene tubes; one empty tube was used as control (Group 1), and the other tubes were filled with ACTIVA (Group 2), iRoot BP (Group 3) and MTA-HP (Group 4). Then, the rats were subdivided into 3 groups according to the sacrification time into one, two and 4 weeks (n = 25 rats). Tissue specimens were submitted to histopathological and immunohistochemical analysis of α-SMA and caspase 3.


The one-way Anova test revealed that ACTIVA group exhibited minimal inflammation in comparison to calcium silicate cements (iRoot BP and MTA-HP groups). iRoot BP group significantly revealed a more severe degree of chronic inflammation in comparison to other groups (P < 0.05). ACTIVA group showed marked regression of inflammation and fibrosis comparable to the control, while iRoot BP group revealed remarkable fibrosis and calcification, with less degrees in MTA-HP group (P < 0.05). Immunostaining of both α-SMA and caspase 3 revealed lower indexes in ACTIVA group consistent with the control (P < 0.05).


ACTIVA showed a higher degree of biocompatibility to subcutaneous tissues in comparison to both iRoot BP and MTA-HP cements in regard to decrease the intensity of inflammation, with subsequent fibrous connective tissue remodeling and better healing patterns.

Clinical significance

Preliminary data suggests that the application of ACTIVA in retrograde fillings.


Endodontic procedural errors may include traumatic pulp exposure and root perforations. Subsequent communication with surrounding periapical tissues may occur, resulting in a challenging situation for operators. A number of different bioactive repair materials can be used to seal these perforations [1]. Biocompatibility and tissue tolerance without election of inflammatory responses are essential prerequisites for a successful endodontic repair material as it comes in direct contact with living human bones, periapical tissues and body fluids [2]. From this point on, finding a suitable material to substitute the lost tooth structure and obtain successful outcomes in such clinical situations, becomes crucial [1].

Mineral Trioxide Aggregate (MTA) provides a great solution due to it’s high biocompatibility, ability to set in presence of water, good sealing ability, bioactivity and other desirable properties for clinical applications [3,4,5]. Despite of its advantages, the disadvantages of MTA include discoloration, long setting time, low flowability and handling difficulties. This led to the need of improvement in physical properties and the development of an enhanced formula to overcome these drawbacks [6].

In 2002, a second generation known as “white MTA” was introduced to the dental markets with smaller and more even particle distributions in order to overcome the drawbacks of grey MTA [7]. MTA Angelus HP (Londrina, PR, Brazil) was introduced with better handling properties and higher plasticity as the manufacturer added an organic plasticizer to the liquid. The manufacturer also replaced bismuth oxide by calcium tungstate as radiopacifier to avoid teeth discoloration. Moreover, the elimination of arsenic and a reduced setting time (15 min) was also accomplished, compared to other MTA based materials [8,9,10].

iRoot BP Plus Root Repair Material (BP-RRM; Innovative BioCeramix Inc., Vancouver, BC, Canada), is a new fully synthetic laboratory material using bioceramic nanotechnology, which is introduced as a ready-to-use premixed bioceramic paste mainly composed of calcium silicate- based compounds. It hardens in the presence of water and needs a minimum of 2 h to completely set. As claimed by the manufacturer, its main advantages are the fact that it is presented in a readymade paste, requiring no mixing, low solubility, high radiopacity, low setting shrinkage and excellent physical properties [11, 12].

The widespread use of composite as root end filling materials is probably hindered by its technique sensitive nature and the requirement for a good moisture control to guarantee a successful adhesion process. Moreover, it may cause local inflammation when it comes in contact with peri-radicular tissues [13]. ACTIVA bioactive composite (Pulpdent, Watertown, MA, USA), as the manufacturer claims, is the first bioactive resin composite material stimulating mineralization at tooth restoration interface with resilient ionic resin matrix [14]. While the approval document obtained from the US Food and Drug Administration (510 k123265) described ACTIVA as self-adhesive dual cured resin modified glass ionomer (RMGI), ACTIVA is claimed to combine the water friendly properties, more release and recharge of calcium, phosphate and fluoride ions than glass ionomers with the durability and improved physical properties of resin- based materials [15].

Although the wide use of these materials as bioactive resin composite for cavity restoration, a potential use may be as a retrofilling materials. To date, no information regarding ACTIVA placed in contact with subcutaneous tissues is reported in literature. Thus, the aim of this study was to compare the biocompatibility of MTA angelus HP, iRoot BP plus and ACTIVA bioactive restorative in terms of inflammatory response, apoptotic activity and healing ability by subcutaneous tissue implants in rats. The current study was designed to test the null hypothesis where there was no difference in the biocompatibility between the three materials.


The tested materials are listed in Table 1.

Table 1 Materials used for the study

Animal study and design

This study was conducted after being approved by the ethical committee of Central South University for animal experiments (No: 20180025). Seventy-five male rats (Rattus norvegicus albinus, Wistar) weighing approximately 180–200 g provided by Institute of Basic and Clinical Pharmacology Research Centre of Hunan Medical University were used according to the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments, 2013) and the procedures conformed to the requirements of the ISO 10993-1 (1992) and ISO 10993-2 (1992) standards [16,17,18]. Animals were kept in an aerated chamber with 12-h dark and light intervals, divided according to study period. The cages were cleaned on a daily basis, and free access to food and water was allowed. Animals were then given water only 12 h before surgery.

Three hundred sterile polyethylene tubes (10 mm in length and 1.3 mm in diameter) were used and filled with the test materials then implanted in the dorsal region underneath the skin of each rat which were divided into 4 groups: (Fig. 1a)

  1. 1.

    Group 1 (Control, n = 75 tubes): Empty polyethylene tubes.

  2. 2.

    Group 2 (ACTIVA, n = 75 tubes): Polyethylene tubes filled with ACTIVA (Pulpdent, USA).

  3. 3.

    Group 3 (iRoot BP, n = 75 tubes): Polyethylene tubes filled with iRoot BP plus (Innovative BioCeramix Inc., Vancouver, BC, Canada).

  4. 4.

    Group 4 (MTA-HP, n = 75 tubes): Polyethylene tubes filled with MTA-HP (Angelus HP, Londrina, PR Brazil).

Fig. 1

a Photograph illustrating the four groups of materials implanted in the dorsal region underneath the skin of each rat. b diagram illustrating the classification of groups according to scarification time

The materials were manipulated according to manufacturers’ instructions. A small condenser was used to insert the test materials into the tubes. The tubes were entirely filled with the tested materials and left for setting. Before surgery, the animals were anesthetized with ketamine hydrochloride and xylazine hydrochloride Intraperitoneal injection (3, 1 respectively; 0.05 mL/100 g of weight; I/P). The dorsal region of each rat was submitted to trichotomy, and antisepsis was done using a gauze moistened with 0.12% chlorhexidine. The dorsal region was then swapped with a gauze soaked with saline solution to remove any antiseptic residue. Four incisions were performed on the dorsal region of each rat (2 anteriorly and 2 posteriorly). The skin lateral to the incisions was pinched, and subcutaneous dissection was done using blunt-ended scissors.

Each animal received 4 tubes: 2 in the anterior dorsal region (Group1 to the left side and group 4 to the right) and 2 tubes in the posterior region (Group 2 to the left side and group 3 to the right). Then, the incisions were closed with Nylon 3–0 sutures. The rats were further subdivided into 3 groups according to the time period of sacrifice into: Group A after 1 week, Group B after 2 weeks and Group C after 4 weeks. (Fig. 1b) By the end of each period, 25 animals were euthanized by administering an anesthetic overdose with ketamine hydrochloride and xylazine hydrochloride Intraperitoneal injection (1: 1 respectively; 0.15 mL/100 g of weight; I/P). Biopsies of skin and subcutaneous tissues (2 × 2 cm) containing the implants were obtained with 1-cm safety margins.

Histological procedures

The subcutaneous tissues containing the tubes were excised, fixed in 10% neutral formalin for 48 h. After that, the specimens were trimmed parallel to the tube leaving at least 2 mm of tissue on each side, cut into two equal halves, and the tubes were removed. Then, the specimens were inserted in serial ascending concentration of ethyl alcohol for dehydration, followed by clearance in xylene and embedded in paraffin at 58–62 C°. Samples were casted parallel to the long axis of the tube to show the region of interest (tube opening) then serial sections of 4 μm thickness were prepared for further staining with hematoxylin & eosin stain (H&E).


Sections from the prepared paraffin blocks were mounted on super frosted coated glass slides (Fisher Thermo Scientific, Nepean, Ontario, Canada) for immunohistochemistry. The sections were cleared, hydrated and subjected to antigen retrieval in EDTA solution (pH = 8) for 15 min at 37 °C. Subsequent incubation of the sections was performed with primary antibodies against α-smooth muscle actin (Thermo Fisher Scientific, Fremont, CA, USA; Cat. No. A1–70007) and caspase 3 (cleaved form of concentrated polyclonal antibody, CP 229A, B, C, 1:200, rabbit, Biocare medical, Pacheco, USA). The slides were rinsed in phosphate buffer saline and incubated with anti-rabbit IgG secondary antibodies (EnVision + System HRP; Dako) for 30 min at room temperature, visualized with di-aminobenzidine commercial kits (Liquid DAB+Substrate Chromogen System; Dako), and finally counterstained with Mayer’s haematoxylin. The negative control sample was prepared with replacing the primary antibody with normal mouse serum.

Assessment of histopathological and immunohistochemical sections of α-SMA and caspase 3

Histological examination was performed using Leica Microscope (Leica Microsystems GmbH, Wetzlar, Germany) adapted with a DFC420 camera. The histopathological grading was evaluated according to the following criteria: necrosis, inflammatory cell infiltrate (polymorph nuclear and mononuclear cells), congestion, macrophage activity (macrophages and multinuclear giant cells which independently scored), vascularization (blood vessels) and fibrosis (fibroblasts). The previous analysis points were scored as (0) absent, (1) discrete, (2) moderate, and (3) severe. The thickness of the fibrous capsule was measured with ImageJ analysis software (NIH, MD, USA) [19,20,21]. The scoring system was performed by an experienced blinded pathologist, and scores were organized on specific sheets. Quantitative scoring of α-SMA and caspase 3 immunostaining were done according to determination of threshold basis using ImageJ software and expressed as the percent of positive area /mm2.

Statistical analysis

Data were analyzed using the GraphPad Prism 4.0 Software (GraphPad Software, La Jolla, CA). The mean range difference between experimental groups was assessed using Kolmogorov- Smirnov test, values of α-SMA and caspase 3 obtained were statistically compared with One-way ANOVA (One-way analysis of variance) and then multiple comparisons were done using Tukey’s test (p < 0.05) to determine the level of significance.


Histopathological findings

Semi quantitative scoring of the histopathological findings of control, ACTIVA, iRoot BP and MTA-HP was illustrated in Table 2. The statistical analysis was conducted on 60 rats because 15 rats were excluded due to either removal of tube or mortality. On the first week, control group showed thin inflammatory wall, with mild fibrin clot associated with minimal tissue necrosis and few macrophages and neutrophils cells infiltration. Marked tissue organization and angiogenesis around the tube were apparently noticed. Calcification or multinuclear giant cells infiltration were completely absent within the examined animals of this group (Fig. 2a and a1). ACTIVA group revealed slight to moderate inflammatory reaction on the tubular orifice. There was slight fibrinous inflammatory response with a pronounced granulation tissue formation and a mild inflammatory cells infiltration consisted of lymphocytes, macrophages and few neutrophils (Fig. 2b and b1). The subcutaneous tissue reaction to iRoot BP group demonstrated thick inflammatory capsule associated with extensive tissue necrosis, black brownish-leaked deposits of the test material, focal calcification as well as marked fibrosis and angiogenesis especially towards the adjacent connective tissues. The cellular inflammatory response in this group predominately showed macrophages and multinuclear giant cells infiltration (Fig. 2c and c1). MTA- HP group showed thin layer of necrotic tissue admixed with tiny fibrin clotted areas, along with the presence of particulates of brownish pigments especially at the tubular opening. Mild to moderate inflammatory reaction, consisted of mononuclear cells infiltration mainly lymphocytes, macrophages and few neutrophils without any apparent multinuclear giant cells. The fibrosis degree was scanty with immature granulation tissue formation (Fig. 2d and d1).

Table 2 Scoring of histopathologic events observed in each group at different time intervals of the study
Fig. 2

Photomicrograph of H&E staining showing the subcutaneous tissue of control, ACTIVA, iRoot BP and MTA-HP after one- and two-weeks exposure. The 1st week, a control tube showing mild inflammatory reaction within and around the capsule, a1 the inset revealing thin capsule with minimal fibrinoid-like deposition infiltrated with few macrophages; b the opening of ACTIVA tube demonstrating moderate degree of inflammation (IR) with marked granulation tissue formation, b1 the inset showing infiltration of lymphocytes and macrophages and with marked fibroblastic activity (curved-arrow); c the iRoot BP tube showing intense inflammatory response, c1 the inset showing marked fibrosis and calcification within the inflammatory area (arrow); d MTA-HP tube showing moderate degree of inflammation, d1 the inset revealing mild inner necrosis associated with macrophages and lymphocytes infiltration. The 2nd week, e Control tube showing an obvious repair of the inflammatory capsule, e1 inset showing marked remodeling of the fibrous connective tissue (curved-arrow); f ACTIVA tube showing marked decrease of necrosis and inflammation f1 the inset showing ample amount of zigzag-like layers of elastic and collagen fibers (crossed-arrow); g iRoot BP tube showing thick capsule with still noticeable intense inflammation g1 the inset showing fibrosis, calcification (arrow) and multinuclear giant cells infiltration (arrowheads); h MTA HP tube showing relatively thick inflammatory capsule, h1 the inset showing leakage of some tube material associated with inflammatory cells infiltration with mild to moderate fibrosis and calcification (arrow). TO: Tube Opening, IR: Inflammatory Reaction, Bv: Blood vessel

On the period of 2 weeks, control group showed an early remodeling of the fibrous connective tissue capsule, mild inflammatory cells infiltration and slight angiogenesis (Fig. 2e and e1). ACTIVA group demonstrated marked decrease in both inflammation and tissue necrosis with regression of inflammatory cells number. The capsule was lined with fibroblast layer, encircled by medial layer of collagen and elastic connective tissues that normally oriented in parallel pattern. The outer layer showed fibrous connective tissue associated with minimal both angiogenesis and inflammatory cells infiltration consisted of macrophages and lymphocytes (Fig. 2f and f1). iRoot BP group showed a noticeable chronic inflammatory reaction at the tube orifice associated with intense fibrosis, calcification and multinuclear giant cells infiltration. Active angiogenesis was markedly increased, not only limited to the tube opening but also extended deeper into the adjacent tissues (Fig. 2g and g1). MTA- HP group revealed similar reaction to the previous group but with a lesser degree regarding the level of calcification, fibrosis and multinuclear giant cells infiltration (Fig. 2h and h1).

After 4 weeks, control group demonstrated thin mature fibrous capsule with sparse inflammatory reaction and with normal continuity to neighboring fibrous and adipose connective tissues (Fig. 3a and a1). ACTIVA group showed progressive healing with abrogation of coagulative necrosis and inflammatory cells aggregation. A well-formed fibrous capsule was consisted mainly of multiple parallel collagen fibers. In addition, marked decrease of the inflammatory reaction was noticed by regression of lymphocytes and macrophages infiltration (Fig. 3b and b1).

Fig. 3

Photomicrograph of H&E staining sections showing the subcutaneous tissue implant of control, ACTIVA iRoot BP and MTA HP after 4 weeks in addition to α-SMA and caspase 3 immunostaining. After 1 month experiment, a control tube showing thin fibrous capsule, a1 the inset revealing normal well organized fibrous connective capsule (FC); b ACTIVA tube showing thin fibrous capsule, b1 the inset showing mild inflammatory cells infiltration, fibroblasts and moderate fibrous connective tissues (curved-arrow); c iRoot BP tube showing relatively thick fibrous capsule FC, c1 the inset showing remodeling of fibrous capsule and collagen fibers (crossed arrow); d MTA HP tube showing thin fibrous capsule, d1 the inset revealing mild pericapsular fibrosis and calcification (arrow). The 3rd panel α-SMA immunostaining within the fibrous capsule, e Control tube, f ACTIVA tube, g iRoot BP tube which showed marked immunostaing and h MTA HP tube. Tailed-arrow indicates the expression α-SMA within myofibroblasts. α-SMA IHC. The 4th panel caspase 3 immunostaining within the fibrous capsule, i Control tube, j ACTIVA tube, k iRoot BP tube and l MTA HP tube. Wavy-arrow indicates caspase 3 immunostaining within the fibrous capsule. Caspase 3 IHC. TO: Tube Opening, IR: Inflammatory Reaction, FC: Fibrous Capsule

iRoot BP group demonstrated moderate inflammation, slight angiogenesis and mineralization alongside the tube orifice. In addition, marked thickening of the fibrous capsule was still noticeable (Fig. 3c and c1). MTA- HP group showed restoration of the normal tissue. However, limited organization of the fibrous capsule and small tiny particulates of mineral deposition were noticed (Fig. 3d and d1).

Immunohistochemistry analyses

α-SMA antibody

The α-SMA antibody was expressed mostly within the myofibroblast. Mild expression was seen within the fibrous capsule of the control tube (Fig. 3e). The fibrous capsule around ACTIVA group tube orifice showed similar expression pattern to the control tube (Fig. 3f). Marked expression of α-SMA was noticed within the fibrous capsule around iRoot BP group tube orifice in comparison with the control tube (p < 0.05) (Fig. 3g). MTA- HP group tube revealed an increase of positive immunostaining in comparison to the control tube (p < 0.05) (Fig. 3h) - (Fig. 4a).

Fig. 4

Representative chart of α-SMA (a) and caspase 3 (b) immunoreaction, data were expressed as percentage of positive area (mean ± SD), # and ## indicate significance at p < 0.01 and 0.001 respectively

Caspase 3 antibody

A positive expression of caspase 3 antibody was noticed mainly within the macrophages and instantly within the fibroblasts. Scanty expression of caspase 3 was noticed within the fibrous capsule around the control tube (Fig. 3i). ACTIVA group tube orifice also showed mild positive reaction (Fig. 3j). Marked increase of caspase 3 positive reaction only appeared within the capsule of iRoot BP group tube in comparison to the control group (p < 0.05) (Fig. 3k). The immunoexpression of caspase 3 within MTA- HP group tube was nearly comparable to iRoot BP group (Fig. 3l) - (Fig. 4b).


Minimum toxicity without provoking significant inflammatory response is a fundamental prerequisite of biocompatible materials [22]. Many trials have been undertaken to develop materials with comparable bioactive properties to that of calcium silicate-based materials. These efforts resulted in emergence of both ACTIVA and TheraCal (Bisco Inc., Schamburg, IL, USA). TheraCal is a light-cured calcium silicate-based liner developed for pulp capping procedures with proven successful biological outcomes [23,24,25,26]. On the other hand, ACTIVA is considered as RMGI, according to the FDA document [27] (Accessed at 13th of June 2019) and has similar bioactivity and biocompatibility as TheraCal, and can also be used as base material (dentine substitute). Most of the endodontic materials are liable to be used in close contact with human tissues in case of perforations, apical barriers and retrograde fillings. Therefore, these materials must be evaluated carefully in the terms of cytotoxicity and biocompatibility to ensure success of the treatment [28].

Two methods are available to assess the biocompatibility, including in vitro studies such as cytotoxicity using cell culture, genotoxicity and in vivo studies including bone implant and subcutaneous tissue surgical placement. Subcutaneous surgical placement of polyethylene tube containing testing material, has been advocated for testing their biocompatibility and the tissue reaction [29]. The similarity between root canal condition and extruded material at the orifice of polyethene tube creates subcutaneous tissue-tube interface which triggers an inflammatory response with adsorption of tissue fluids and blood into the tube site [30].

Subcutaneous surgical placement of ACTIVA resulted in fast healing with moderate pleomorphic nuclear leukocytes (PMNs), lymphocytes infiltration, early granulation tissue formation and a well formed medium fibrous capsule after a 4 week post-implantation similar to the control group. Biocompatibility of resin containing materials is highly affected by the volume and nature of its leachable elements [31]. Hence the good results of ACTIVA might be due to absence of bisphenol A, Bis-GMA and BPA derivatives which are well known as a serious hazard and aetiologies to irreversible effects on living cells [32]. These results were consistent with the findings [24, 25] with TheraCal showing superior biocompatibility and stimulating more osteoblast-like cells growth and differentiation compared to MTA.

Meanwhile, iRoot BP tubes revealed an initial intense inflammation with an appearance of multi nuclear giant cells (MNGCs) and extensive fibrosis with evidence of bio mineralization and mineral deposition, which was extended untill the 4th week and a thick capsular formation was observed. Furthermore, the MTA-HP implant demonstrated similar chronic nature of tissue response with bio mineralization activity also, but with a lesser degree and a smaller capsular formation than that observed with iRoot BP. These findings were supported by previous studies [33, 34] who reported that both MTA Angelus and iRoot BP exhibited higher fibroblast induction and production of bioactive molecules in comparison to ProRoot MTA .

White MTA-HP had better biocompatibility and wound healing in comparison to iRoot BP and did not induce significant necrosis or apoptosis [35]. Removal of bismuth oxide from the constituents of MTA HP significantly reduced the cytotoxicity affecting osteoblasts and dental pulp cells, particularly when combined with dicalcium silicate [36].

Also, iRoot BP was reported to reduce the cell viability of osteoblast cells in comparison to MTA [12, 37]. And similarly, another study reported that higher concentrations of MTA suppressed cell viability and sialoprotein production of cementoblasts [38]. In addition, high alkalinity of MTA initially induced severe inflammation associated with coagulative necrosis and dystrophic calcifications within superficial cell layers of adjacent connective tissues [6, 39].

Different phases of Calcium silicate hydrate are formed by hydration during a mixing process [40]. Moisture severely affects the bioactivity of the cement starting from the nucleation process of calcium ions until the formation of portlandite occurs. The continuous outflux of calcium hydroxide from CSH helps portlandite crystals to nucleate inside the hydrating wet paste. Calcium phosphate and apatite deposit on cement surfaces as a result of exposure to tissue fluids after being placed subcutaneously [4, 41].

The hydrophobic nature of resin components incorporated in light-cured calcium silicate-based materials decreases its solubility compared to MTA. The resin matrix contains pores which allow water penetration in both in and out directions, thus justifying their ability of calcium ions solubilization and formation of calcium silicate hydrate and portlandite [25, 42, 43].

In the study by Zamparini et al. [44] ready-made paste bioceramic materials containing tantalum pentoxide as radiopacifier showed higher calcium and silicate ions release. In addition there is a direct correlation between calcium ions released from such materials and the proliferation and differentiation of pluripotent-mesenchymal cells into osteoblast like cells regardless the pH level [45].

The contact between the retrograde filling materials and subcutaneous tissue cells induce injury. The healing process within the fibrous capsule depends mainly on the myofibroblast-positive α-SMA. Alpha-SMA is a mechanosensitive protein, that has a direct role in β- cytoplasmic actin stress fibers deposition and improving fibroblast contraction after granulation tissue formation [46]. The decreased α-SMA expression level observed in control and ACTIVA groups was related to less fibrosis formation in comparison with iRoot BP and MTA HP groups that showed intense fibrous reaction.

Apoptosis has a principal role in the repair process mainly in removal of granulation tissue and inflammatory cells which mostly mediate through caspase enzymes. Caspases are a cysteine-requiring aspartate protease that are critically involved in this process. Interestingly, the ACTIVA revealed a marked decrease caspase 3 expression. However, a significant increase in caspase 3 expression in iRoot BP and MTA-HP groups could indicate the ongoing tissue damage. It is noteworthy that many myofibroblast showed apoptosis-like cell death mechanisms in the late stage of wound healing, which might be responsible for disappearance of myofibroblast [47]. Thus, the higher expression index of caspase 3 in the iRoot BP and MTA-HP may indicate a delayed maturation phase of capsule healing consistent with still present myofibroblasts within the fibrous capsule [48].

Periapical area after root end surgery exhibit a challenging environment for retrograde filling materials due to the presence of moisture, blood contamination, bone defects and difficult accessibility. Excessive moisture or blood contamination will have an adverse effect on the mechanical properties and sealing abilities of RMGI and calcium silicate- based materials although; the later use moisture/water for their setting [49, 50]. Occasional challenges faced with MTA represented by the difficulties in manipulation and long setting time increase the possibility of dislocation by irrigating solutions or early occlusal loading [51]. Nevertheless the bioactive RMGI showed promising outcome in previous studies this may be attributed to the bioactivity of this material and high reactivity towards water which plays a great role in deposition of crystals in the exposure sites [52].


In light of the results of this study, it is concluded that a new bioactive RMGI (ACTIVA) exhibited excellent biocompatibility and healing ability for rat subcutaneous tissues in comparison with calcium silicate- based cements. Therefore, further studies for the biological and mechanical properties of this new bioactive RMGI are needed.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.



Inflammatory reaction


Multi nuclear Giant cells


Pleomorphic nuclear leukocytes


Resin modified glass ionomer


  1. 1.

    de Sousa Reis M, Scarparo RK, Steier L, de Figueiredo JAP. Periradicular inflammatory response, bone resorption, and cementum repair after sealing of furcation perforation with mineral trioxide aggregate (MTA Angelus™) or biodentine™. Clin Oral Investig; 2019.

  2. 2.

    Lv F, Zhu L, Zhang J, Yu J, Cheng X, Peng B. Evaluation of the in vitro biocompatibility of a new fast-setting ready-to-use root filling and repair material. Int Endod J. 2017;50(6):540–8.

  3. 3.

    Torabinejad M, Chivian N. Clinical applications of mineral trioxide aggregate. J Endod. 1999;25(3):197–205.

  4. 4.

    Prati C, Gandolfi MG. Calcium silicate bioactive cements: biological perspectives and clinical applications. Dent Mater. 2015;31(4):351–70.

  5. 5.

    L-n N, Jiao K, Zhang W, Camilleri J, Bergeron BE, H-l F, Mao J, Chen J-h, Pashley DH, Tay FR. A review of the bioactivity of hydraulic calcium silicate cements. J Dent. 2014;42(5):517–33.

  6. 6.

    Parirokh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—part I: chemical, physical, and antibacterial properties. J Endod. 2010;36(1):16–27.

  7. 7.

    Camilleri J, Pitt Ford T. Mineral trioxide aggregate: a review of the constituents and biological properties of the material. Int Endod J. 2006;39(10):747–54.

  8. 8.

    De-Deus G, de Souza MCB, Fidel RAS, Fidel SR, de Campos RC, Luna AS. Negligible expression of arsenic in some commercially available brands of Portland cement and mineral trioxide aggregate. J Endod. 2009;35(6):887–90.

  9. 9.

    Bramante CM, Demarchi ACCO, de Moraes IG, Bernadineli N, Garcia RB, Spångberg LS, Duarte MAH. Presence of arsenic in different types of MTA and white and gray Portland cement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(6):909–13.

  10. 10.

    Mineral trioxide aggregate-High Plasticity (MTA-HP) pamphlet, Angelus Co., Londrina. Accessed 17 Aug 2019.

  11. 11.

    Damlar I, Ozcan E, Yula E, Yalcin M, Celik S. Antimicrobial effects of several calcium silicate-based root-end filling materials. Dent Mater J. 2014;33(4):453–7.

  12. 12.

    De-Deus G, Canabarro A, Alves G, Marins J, Linhares A, Granjeiro J. Cytocompatibility of the ready-to-use bioceramic putty repair cement iRoot BP plus with primary human osteoblasts. Int Endod J. 2012;45(6):508–13.

  13. 13.

    Bodrumlu E. Biocompatibility of retrograde root filling materials: a review. Aust Dent J. 2008;34(1):30–5.

  14. 14.

    Activa (Bioactive restorative material) pamphlet, Pulpdent Co., Watertown. Accessed 17 Aug 2019.

  15. 15.

    Pameijer CH, Garcia-Godoy F, Morrow BR, Jefferies SR. Flexural strength and flexural fatigue properties of resin-modified glass ionomers. J Clin Dent. 2015;26(1):23–7.

  16. 16.

    Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31(1):81–110.

  17. 17.

    Wallin RF. A practical guide to ISO 10993: part 1&# 151; introduction to the standards; 1998.

  18. 18.

    Zmener O, Lalis RM, Pameijer CH, Chaves C, Kokubu G, Grana D. Reaction of rat subcutaneous connective tissue to a mineral trioxide aggregate–based and a zinc oxide and eugenol sealer. J Endod. 2012;38(9):1233–8.

  19. 19.

    Parirokh M, Mirsoltani B, Raoof M, Tabrizchi H, Haghdoost A. Comparative study of subcutaneous tissue responses to a novel root-end filling material and white and grey mineral trioxide aggregate. Int Endod J. 2011;44(4):283–9.

  20. 20.

    Stanford J. Recommendations for determining biocompatibility and safety for the clinical use of metals in dentistry. Int Dent J. 1986;36(1):45–8.

  21. 21.

    Garcia LFR, Huck C, de Oliveira LM, de Souza PPC, de Souza Costa CA. Biocompatibility of new calcium aluminate cement: tissue reaction and expression of inflammatory mediators and cytokines. J Endod. 2014;40(12):2024–9.

  22. 22.

    Mori GG, De Moraes IG, Nunes DC, Castilho LR, Poi WR, Capaldi MLPM. Biocompatibility evaluation of alendronate paste in rat’s subcutaneous tissue. Dent Traumatol. 2009;25(2):209–12.

  23. 23.

    Arandi NZ, Rabi T. TheraCal LC: from biochemical and bioactive properties to clinical applications. Int J Dent. 2018;2018:3484653.

  24. 24.

    Buonavoglia A, Lauritano D, Perrone D, Ardito F, Troiano G, Dioguardi M, Candotto V, Silvestre F, Lo LM. Evaluation of chemical-physical properties and cytocompatibility of TheraCal LC. J Biol Regul Homeost Agents. 2017;31(2 Suppl 1):1–9.

  25. 25.

    Gandolfi MG, Taddei P, Siboni F, Modena E, Ciapetti G, Prati C. Development of the foremost light-curable calcium-silicate MTA cement as root-end in oral surgery. Chemical–physical properties, bioactivity and biological behavior. Dent Mater. 2011;27(7):e134–57.

  26. 26.

    Gandolfi M, Siboni F, Prati C. Chemical–physical properties of TheraCal, a novel light-curable MTA-like material for pulp capping. Int Endod J. 2012;45(6):571–9.

  27. 27.

    The United States Food and Drug Adminsteration (FDA) approval documnets for Activa restorative materials (Pulpdent Co., Watertown, MA, USA) - FDA Product Code: EMA, 21 CFR Part 872.3275. Accessed 17 Aug 2019.

  28. 28.

    Minotti PG, Ordinola-Zapata R, Midena RZ, Marciano MA, Cavenago BC, Bramante CM, Garcia RB, Duarte MAH, IGd M. Rat subcutaneous tissue response to calcium silicate containing different arsenic concentrations. J Appl Oral Sci. 2015;23(1):42–8.

  29. 29.

    Olsson B, Sliwkowski A, Langeland K. Subcutaneous implantation for the biological evaluation of endodontic materials. J Endod. 1981;7(8):355–69.

  30. 30.

    Shahi S, Rahimi S, Lotfi M, Yavari H, Gaderian A. A comparative study of the biocompatibility of three root-end filling materials in rat connective tissue. J Endod. 2006;32(8):776–80.

  31. 31.

    Geurtsen W. Biocompatibility of resin-modified filling materials. Crit Rev Oral Biol Med. 2000;11(3):333–55.

  32. 32.

    Hanks C, Strawn S, Watahai J, Craig R. Cytotoxic effects of resin components on cultured mammalian fibroblasts. J Dent Res. 1991;70(11):1450–5.

  33. 33.

    Jiang Y, Zheng Q, Zhou X, Gao Y, Huang D. A comparative study on root canal repair materials: a cytocompatibility assessment in L929 and MG63 cells. ScientificWorldJournal. 2014;2014:463826.

  34. 34.

    Guven G, Cehreli ZC, Ural A, Serdar MA, Basak F. Effect of mineral trioxide aggregate cements on transforming growth factor β1 and bone morphogenetic protein production by human fibroblasts in vitro. J Endod. 2007;33(4):447–50.

  35. 35.

    Bin CV, Valera MC, Camargo SE, Rabelo SB, Silva GO, Balducci I, Camargo CHR. Cytotoxicity and genotoxicity of root canal sealers based on mineral trioxide aggregate. J Endod. 2012;38(4):495–500.

  36. 36.

    Chiang T-Y, Ding S-J. Comparative physicochemical and biocompatible properties of radiopaque dicalcium silicate cement and mineral trioxide aggregate. J Endod. 2010;36(10):1683–7.

  37. 37.

    Modareszadeh MR, Di Fiore PM, Tipton DA, Salamat N. Cytotoxicity and alkaline phosphatase activity evaluation of endosequence root repair material. J Endod. 2012;38(8):1101–5.

  38. 38.

    Torabinejad M, Parirokh M. Mineral trioxide aggregate: a comprehensive literature review—part II: leakage and biocompatibility investigations. J Endod. 2010;36(2):190–202.

  39. 39.

    Yaltirik M, Ozbas H, Bilgic B, Issever H. Reactions of connective tissue to mineral trioxide aggregate and amalgam. J Endod. 2004;30(2):95–9.

  40. 40.

    Gandolfi M, Iezzi G, Piattelli A, Prati C, Scarano A. Osteoinductive potential and bone-bonding ability of ProRoot MTA, MTA plus and biodentine in rabbit intramedullary model: microchemical characterization and histological analysis. Dent Mater. 2017;33(5):e221–38.

  41. 41.

    Han L, Okiji T. Bioactivity evaluation of three calcium silicate-based endodontic materials. Int Endod J. 2013;46(9):808–14.

  42. 42.

    Salles LP, Gomes-Cornélio AL, Guimarães FC, Herrera BS, Bao SN, Rossa-Junior C, Guerreiro-Tanomaru JM, Tanomaru-Filho M. Mineral trioxide aggregate–based endodontic sealer stimulates hydroxyapatite nucleation in human osteoblast-like cell culture. J Endod. 2012;38(7):971–6.

  43. 43.

    Von Arx T. Mineral trioxide aggregate (MTA) a success story in apical surgery. Swiss Dent J. 2016;126(6):573.

  44. 44.

    Zamparini F, Siboni F, Prati C, Taddei P, Gandolfi MG. Properties of calcium silicate-monobasic calcium phosphate materials for endodontics containing tantalum pentoxide and zirconium oxide. Clin Oral Investig. 2019;23(1):445–57.

  45. 45.

    Matsumoto S, Hayashi M, Suzuki Y, Suzuki N, Maeno M, Ogiso B. Calcium ions released from mineral trioxide aggregate convert the differentiation pathway of C2C12 cells into osteoblast lineage. J Endod. 2013;39(1):68–75.

  46. 46.

    Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat M-L, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–16.

  47. 47.

    Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995;146(1):56.

  48. 48.

    Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):839–47.

  49. 49.

    Nekoofar MH, Davies T, Stone D, Basturk F, Dummer PMH. Microstructure and chemical analysis of blood-contaminated mineral trioxide aggregate. Int Endod J. 2011;44(11):1011–8.

  50. 50.

    Biočanin V, Antonijević Đ, Poštić S, Ilić D, Vuković Z, Milić M, Fan Y, Li Z, Brković B, Đurić M. Marginal gaps between 2 calcium silicate and glass ionomer cements and apical root dentin. J Endod. 2018;44(5):816–21.

  51. 51.

    Haapasalo M, Parhar M, Huang X, Wei X, Lin J, Shen Y. Clinical use of bioceramic materials. Endod Topics. 2015;32(1):97–117.

  52. 52.

    van Dijken JW, Pallesen U, Benetti A. A randomized controlled evaluation of posterior resin restorations of an altered resin modified glass-ionomer cement with claimed bioactivity. Dent Mater. 2019;35(2):335–43.

Download references


The author denies any conflict of interest to disclose. The authors would like to thank Angelus (Londrina, PR, Brazil) and Pulpdent (Watertown, MA, USA) companies for donating the materials used in this study.


This study was supported by research grant No: 2019 JJ40209 funded by The Natural Science Foundation of Hunan Province, Republic of China. The fund is directed to the animal purchased, housing, procedures, materials and equipment used for this study.

Author information

AA performed all the steps of the study plus writing the initial form of the manuscript. HH participated in planning and guiding the study plan and final editing of the manuscript. WA analyzed and interpreted the data regarding the inflammatory response as a blind examiner. QW participated in the experimental steps and collecting data. AZ participated in editing and reviewing the final manuscript. XX major contributor in writing the manuscript and put the study design. All authors have read and approved the manuscript.

Correspondence to Xie Xiaoli.

Ethics declarations

Ethics approval

This study was conducted after approval of the ethical committee of Central South University on animal experiments (No: 20180025). All applicable international, national, and / or institutional guidelines for the care and use of animals were followed.

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abou ElReash, A., Hamama, H., Abdo, W. et al. Biocompatibility of new bioactive resin composite versus calcium silicate cements: an animal study. BMC Oral Health 19, 194 (2019).

Download citation


  • Bioactive composite
  • Calcium silicate
  • Caspase 3
  • MTA-HP
  • α-SMA